| | N | % |
---|
Age | [0–16] | 9 | 5.3 |
[16–59] | 131 | 78.4 |
[60-] | 27 | 16.1 |
Sex | Female | 83 | 49,7 |
Male | 84 | 50.2 |
Ethnic group | Sub-Saharan Africans | 139 | 83,2 |
Non sub-Saharan Africansa | 28 | 16.7 |
Country of acquisition | Cameroon | 104 | 62.2 |
Gabon | 27 | 16.1 |
Congo-Brazzaville | 16 | 9.5 |
Central African Republic | 6 | 3.5 |
Othersb | 8 | 4.7 |
Undetermined | 6 | 3.8 |
Symptoms c,d | Itching | 74 | 44.3 |
Calabar swelling | 54 | 32,3 |
Subcutaneous oedema | 29 | 17.3 |
Eyeworm | 39 | 23.3 |
Other ocular symptoms | 24 | 14.3 |
Subcutaneous worm migration | 8 | 4.7 |
No symptom | 45 | 26.9 |
- aNon sub-Saharan African patients = Europeans (N = 26) and patients from North Africa (N = 2)
- bother countries: Benin, Ivory Coast, Equatorial Guinea, Mali, Rwanda, Democratic Republic of Congo
- ctotal percentage of different symptoms exceeds 100% as one patient may have presented several symptoms simultaneously
- dmain data from the 3 patients who reported non-endemic countries as countries of contamination (see discussion): Ivory Coast: VFR, itching, microfilaremia: 3/mL; Mali (South): VFR, stay of 3 months, itching, microfilaremia: 4/mL; Rwanda: VFR, subcutaneous oedema (ankle), serology + with specific arc at immunoelectrophoresis